Patents by Inventor Maoliang Wang

Maoliang Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100273236
    Abstract: The invention provides a recombinant Escherichia coli host cell for producing an Escherichia coli L-asparaginase II enzyme. The host cell includes an Escherichia coli chromosome and at least one copy of a recombinant extrachromosomal vector, wherein the recombinant extrachromosomal vector encodes the L-asparaginase II enzyme, wherein the host cell chromosome also encodes the same L-asparaginase II enzyme, and wherein the host chromosome does not encode any other isoform of L-asparaginase II.
    Type: Application
    Filed: May 4, 2010
    Publication date: October 28, 2010
    Applicant: DEFIANTE FARMACEUTICA, S.A.
    Inventors: David Ray FILPULA, Maoliang WANG
  • Patent number: 7807436
    Abstract: The invention provides a recombinant Escherichia coli host cell for producing an Escherichia coli-asparaginase II enzyme. The host cell includes an Escherichia coli chromosome and at least one copy of a recombinant extrachromosomal vector, wherein the recombinant extrachromosomal vector encodes the L-asparaginase II enzyme, wherein the host cell chromosome also encodes the same L-asparaginase II enzyme, and wherein the host chromosome does not encode any other isoform of L-asparaginase II.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: October 5, 2010
    Assignee: Defiante Farmaceutica, S.A.
    Inventors: David Ray Filpula, Maoliang Wang
  • Publication number: 20090214472
    Abstract: Biologically-active, interferon-beta 1b-polymer conjugate compositions are disclosed. The polymer portion is preferably a polyalkylene oxide polymer having a molecular weight of at least about 12 kDa. Methods of making and using the same are also disclosed.
    Type: Application
    Filed: February 28, 2005
    Publication date: August 27, 2009
    Applicant: ENZON PHARMACEUTICALS INC.
    Inventors: David Ray Filpula, Karen Yang, Amartya Basu, Maoliang Wang
  • Publication number: 20080063632
    Abstract: The invention provides a recombinant Escherichia coli host cell for producing an Escherichia coli-asparaginase II enzyme. The host cell includes an Escherichia coli chromosome and at least one copy of a recombinant extrachromosomal vector, wherein the recombinant extrachromosomal vector encodes the L-asparaginase II enzyme, wherein the host cell chromosome also encodes the same L-asparaginase II enzyme, and wherein the host chromosome does not encode any other isoform of L-asparaginase II.
    Type: Application
    Filed: June 8, 2007
    Publication date: March 13, 2008
    Inventors: David Filpula, Maoliang Wang
  • Publication number: 20050042680
    Abstract: The present invention relates to monovalent and multivalent single-chain antigen-binding polypeptides with site-specific modifications. The provided polypeptides are capable of being covalently linked or conjugated to polyalkylene oxides at the modified sites. The resulting conjugates retain antigen binding properties and exhibit prolonged circulating time and reduced antigenicity relative to unconjugated single chain antigen binding polypeptides. Methods and compositions for making and using the single chain antigen-binding polypeptides with site-specific modifications are also provided.
    Type: Application
    Filed: April 23, 2004
    Publication date: February 24, 2005
    Inventors: David Filpula, Karen Yang, Amartya Basu, Maoliang Wang
  • Patent number: 6764853
    Abstract: The present invention is directed to a method of in vivo and ex vivo gene delivery, for a variety of cells. More specifically, it relates to a novel carrier system and method for targeted delivery of nucleic acids to mammalian cells. More specifically, the present invention relates to carrier system comprising single-chain polypeptide binding molecules having an a region rich in basic amino acid and having the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. The basic amino acid rich region can comprise oligo-lysine, oligo-arginine or combinations thereof. Such preparations of modified single chain polypeptide binding molecules also have ability to bind nucleic acids at the region rich in basic amino acid residues. These properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications including gene therapy.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: July 20, 2004
    Assignee: Enzon Pharmaceuticals, Inc.
    Inventors: David R. Filpula, Maoliang Wang, Marc D. Whitlow
  • Patent number: 6743896
    Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: June 1, 2004
    Assignee: Enzon, Inc.
    Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
  • Patent number: 6743908
    Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: June 1, 2004
    Assignee: Enzon, Inc.
    Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
  • Patent number: 6692942
    Abstract: The present invention is directed to a method of in vivo and ex vivo gene delivery, for a variety of cells. More specifically, it relates to a novel carrier system and method for targeted delivery of nucleic acids to mammalian cells. More specifically, the present invention relates to carrier system comprising single-chain polypeptide binding molecules having an a region rich in basic amino acid and having the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. The basic amino acid rich region can comprise oligo-lysine, oligo-arginine or combinations thereof. Such preparations of modified single chain polypeptide binding molecules also have ability to bind nucleic acids at the region rich in basic amino acid residues. These properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications including gene therapy.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: February 17, 2004
    Assignee: Enzon, Inc.
    Inventors: David R. Filpula, Maoliang Wang, Marc D. Whitlow
  • Publication number: 20040009166
    Abstract: The present invention relates to monovalent and multivalent single-chain antigen-binding polypeptides with site-specific modifications. The provided polypeptides are capable of being covalently linked or conjugated to polyalkylene oxides at the modified sites. The resulting conjugates retain antigen binding properties and exhibit prolonged circulating time and reduced antigenicity relative to unconjugated single chain antigen binding polypeptides. Methods and compositions for making and using the single chain antigen-binding polypeptides with site-specific modifications are also provided.
    Type: Application
    Filed: April 25, 2003
    Publication date: January 15, 2004
    Inventors: David R. Filpula, Karen Yang, Amartya Basu, Maoliang Wang
  • Publication number: 20020161201
    Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.
    Type: Application
    Filed: September 20, 2001
    Publication date: October 31, 2002
    Applicant: Enzon, Inc.
    Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
  • Publication number: 20020155498
    Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.
    Type: Application
    Filed: September 20, 2001
    Publication date: October 24, 2002
    Applicant: Enzon, Inc.
    Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
  • Publication number: 20020156248
    Abstract: The present invention is directed to a method of in vivo and ex vivo gene delivery, for a variety of cells. More specifically, it relates to a novel carrier system and method for targeted delivery of nucleic acids to mammalian cells. More specifically, the present invention relates to carrier system comprising single-chain polypeptide binding molecules having an a region rich in basic amino acid and having the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. The basic amino acid rich region can comprise oligo-lysine, oligo-arginine or combinations thereof. Such preparations of modified single chain polypeptide binding molecules also have ability to bind nucleic acids at the region rich in basic amino acid residues. These properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications including gene therapy.
    Type: Application
    Filed: November 2, 2001
    Publication date: October 24, 2002
    Applicant: Enzon, Inc.
    Inventors: David R. Filpula, Maoliang Wang, Marc D. Whitlow
  • Publication number: 20020151061
    Abstract: The present invention is directed to a method of in vivo and ex vivo gene delivery, for a variety of cells. More specifically, it relates to a novel carrier system and method for targeted delivery of nucleic acids to mammalian cells. More specifically, the present invention relates to carrier system comprising single-chain polypeptide binding molecules having an a region rich in basic amino acid and having the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. The basic amino acid rich region can comprise oligo-lysine, oligo-arginine or combinations thereof. Such preparations of modified single chain polypeptide binding molecules also have ability to bind nucleic acids at the region rich in basic amino acid residues. These properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications including gene therapy.
    Type: Application
    Filed: October 25, 2001
    Publication date: October 17, 2002
    Inventors: David R. Filpula, Maoliang Wang, Marc D. Whitlow
  • Patent number: 6333396
    Abstract: The present invention is directed to a method of in vivo and ex vivo gene delivery, for a variety of cells. More specifically, it relates to a novel carrier system and method for targeted delivery of nucleic acids to mammalian cells. More specifically, the present invention relates to carrier system comprising single-chain polypeptide binding molecules having an a region rich in basic amino acid and having the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. The basic amino acid rich region can comprise oligo-lysine, oligo-arginine or combinations thereof. Such preparations of modified single chain polypeptide binding molecules also have ability to bind nucleic acids at the region rich in basic amino acid residues. These properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications including gene therapy.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: December 25, 2001
    Assignee: Enzon, Inc.
    Inventors: David R. Filpula, Maoliang Wang, Marc D. Whitlow
  • Patent number: 6323322
    Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.
    Type: Grant
    Filed: April 30, 1998
    Date of Patent: November 27, 2001
    Assignee: Enzon, Inc.
    Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
  • Patent number: 6132713
    Abstract: A purified arginine deiminase (ADI) obtained from Mycoplasma arthritidis having the amino acid sequence of SEQ ID NO:2 as well as an isolated nucleic acid molecule containing a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:1 are disclosed. Other aspects of the invention include an expression vector, a cloned gene for expressing the Mycoplasma arthritidis derived ADI, (recombinant) host cells useful in expressing the ADI of the present invention and substantially non-antigenic polymer conjugates containing the ADI of the present invention as well as methods of treating arginine deiminase susceptible conditions in mammals. The arginine deiminase-polymer conjugates have high levels of retained enzyme activity and relatively long circulating lives.
    Type: Grant
    Filed: March 18, 1999
    Date of Patent: October 17, 2000
    Assignee: Enzon, Inc.
    Inventors: David Ray Fiipula, Maoliang Wang
  • Patent number: 5916793
    Abstract: A purified arginine deiminase (ADI) obtained from Mycoplasma arthritidis having the amino acid sequence of SEQ ID NO:2 as well as an isolated nucleic acid molecule containing a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:1 are disclosed. Other aspects of the invention include an expression vector, a cloned gene for expressing the Mycoplasma arthritidis derived ADI, (recombinant) host cells useful in expressing the ADI of the present invention and substantially non-antigenic polymer conjugates containing the ADI of the present invention as well as methods of treating arginine deiminase susceptible conditions in mammals. The arginine deiminase-polymer conjugates have high levels of retained enzyme activity and relatively long circulating lives.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: June 29, 1999
    Assignee: Enzon, Inc.
    Inventors: David Ray Filpula, Maoliang Wang
  • Patent number: 5804183
    Abstract: A purified arginine deiminase (ADI) obtained from Mycoplasma arthritidis having the amino acid sequence of SEQ ID NO:2 as well as an isolated nucleic acid molecule containing a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:1 are disclosed. Other aspects of the invention include an expression vector, a cloned gene for expressing the Mycoplasma arthritidis derived ADI, (recombinant) host cells useful in expressing the ADI of the present invention and substantially non-antigenic polymer conjugates containing the ADI of the present invention as well as methods of treating arginine deiminase susceptible conditions in mammals. The arginine deiminase-polymer conjugates have high levels of retained enzyme activity and relatively long circulating lives.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: September 8, 1998
    Assignee: Enzon, Inc.
    Inventors: David Ray Filpula, Maoliang Wang